Navigation Links
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone

cebo once-daily for 14 days (3 saxagliptin, 1 placebo ratio, n=8 subjects/dose panel).

Study 2 consisted of 50 healthy subjects (ages 18-45) who were randomized to receive 40, 100, 150, 200, 300 or 400 mg saxagliptin or matching placebo once daily for 14 days. Within each panel, 6 subjects received 100, 150, 200, 300 or 400 mg saxagliptin, 2 subjects received 40 mg saxagliptin and 2 subjects received matching placebo.

In both studies, there were no deaths or serious adverse events. Additionally, no adverse events of hypoglycemia were reported by investigators. In Study 2, one participant experienced an adverse event (mild rash), which resulted in discontinuation from the study while taking 200 mg of saxagliptin once daily.

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes, accounting for approximately 90-95 percent of diabetes cases. Having Type 2 diabetes increases the risk of many serious complications, including heart disease or stroke, high blood pressure, amputation (particularly legs), blindness, nerve damage, and kidney failure. The risk of stroke and the rate of deaths due to heart disease are two to four times higher among people with diabetes, and about 65 percent of deaths among people with diabetes are due to heart disease and stroke.

The A1C test (also known as hemoglobin A1C) is used primarily to monitor the glucose control of diabetics over time. The goal of those with diabetes is to keep their blood glucose levels as close to normal as possible. This helps to minimize the complications caused by chronically elevated glucose levels, such as progressive damage to body organs like the kidneys, eyes, cardiovascular system, and nerves. The A1C test gives a picture of the average amount of glucose in the blood over the last few months. It can help a patient and his doctor know if the measures they are taking to control the patient's diabetes are successful or need to be adjusted.

About Saxag
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
5. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
6. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
8. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/12/2008)...NGTON, Oct. 12 /- Boston,Sc... results from an analysis,of nearly 7,500 patients...re designed to confirm the performance of the TAXU...t System in real-world practice. The,two-year pool... clinical,restenosis in patients with diabetes as ...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 1Allscripts to Announce First Quarter 2008 Results on April 30 17431 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 1Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 2Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 4DURECT to Participate in Morgan Stanley Global Healthcare Conference 17424 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
(Date:10/13/2008)... AtlantaJobs.com and numerous newspaper affil...tlantaJobs.com . AtlantaJobs.com is the newest on...yers and jobseekers in the metro Atlanta area. , ...r 13, 2008 -- AtlantaJobs.com and numerous newsp... of AtlantaJobs.com is the newest online job boa...
(Date:10/12/2008)... /PRNewswire-USNewswire/ -- Several of Chicago,s,p...n an evening of sampling,and tasting on Monday, No...Chefs Auction. Celebrity Chef and March of Dimes s...Hell,s Kitchen (season 3) will also be in,attendan...-rich recipe for,women considering becoming pregna...
(Date:10/11/2008)...n online survey for World Arthritis Day (WAD), com...cess to psychological support and self-management ...m cope more effectively with their condition and a...onals, people with rheumatic disease and their car...portance of integrating psychological support into...
(Date:10/11/2008)...t International Transcends Cultural Divides, JOHA...uth African and,international audiences welcome Bi...ectrifying gathering, which for the first time is ...: http://www.newscom.com/cgi-bin/prnh/20081011/CL...cked off with performances by,South Africa,s own m...
Breaking Medicine News(10 mins):Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:Sample Signature Dishes of Chicago's Finest Chefs at the March of Dimes Chicago Signature Chefs Auction on Monday, November 10, 2008 2Health News:Call for new standards of care in arthritis/rheumatism 2Health News:Bishop T.D. Jakes Electrifies South Africa 2
...ts have developed a new minimally invasive method ... trials on individuals with prostate cancer soon ....le electroporation (IRE) is a result of the effort...r Rafael V. Davalos and University of California b...
...anners with standard commercial software designed ...ing coronary artery disease in as many as 40 perce..., professor in the Division of Cardiology at The U...ouston, said he discovered the abnormalities upon ...
..., a nanotechnology development company that is dev...lmonella announced today an update regarding its p...e Company stated that although it had received mul...d testing from its contract manufacturer, due to i...
...ing centre was Friday forced to call in police whe...ed overnight, demanded to be let in for the launch... that by Friday morning as many as two thousand pe...'s upmarket Landmark centre to buy the creation of...
Other Medicine News:Health News:Scientists Destroy Cancer Cells Using Electric Pulses 2Health News:Inaccuracies in Cardiac PET-CT Scanning 2Health News:Inaccuracies in Cardiac PET-CT Scanning 3Health News:NanoSensors Provides Update on Its Biosensor to Detect E.coli and Salmonella 2Health News:Designer Bag Launch Causes Shopping Chaos in Hong Kong 2
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII.
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests.
Medicine Products: